Nicolas Bréchot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nicolas Bréchot has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Alain Combes
Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France
7 shared publications Alain Combes
Service de Médecine Intensive-Réanimation, Institut de Cardiologie, Assistance Publique–Hôpitaux de Paris (APHP), Hôpital Pitié–Salpêtrière, Paris, France
6 shared publicationsCharles-Edouard Luyt
Service de Médecine Intensive-Réanimation, Institut de Cardiologie, Assistance Publique–Hôpitaux de Paris (APHP), Hôpital Pitié–Salpêtrière, Paris, France
6 shared publications- Charles-Edouard Luyt
Médecine Intensive Réanimation, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris, France
6 shared publications - Guillaume Lebreton
Service de Chirurgie Cardiaque et Thoracique, Institut de Cardiologie, AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
6 shared publications - Guillaume Hekimian
Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation , Paris
5 shared publications
Latest Publications
- Open Access
- 4 July 2026
- Published by Elsevier in Resuscitation
- Vol. 226, 111196
Sedation Early After Return of Spontaneous Circulation and During Pre-Hospital Transport After Out-Of-Hospital Cardiac Arrest: Retrospective Analysis of the AfterROSC1 & 2 Database
- 4 July 2026
- Published by Elsevier in Resuscitation
- Vol. 226, 111196
Open AccessSedation Early After Return of Spontaneous Circulation and During Pre-Hospital Transport After Out-Of-Hospital Cardiac Arrest: Retrospective Analysis of the AfterROSC1 & 2 Database
- 26 June 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (11) , 2847-2851
Acquired Willebrand syndrome during continuous or pulsatile extracorporeal carbon dioxide removal
- 26 June 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (11) , 2847-2851
Acquired Willebrand syndrome during continuous or pulsatile extracorporeal carbon dioxide removal
- Open Access
- 12 January 2026
- Published by Societe de Reanimation de Langue Francaise in Médecine Intensive Réanimation
- Vol. 34 (4)
Impact hémodynamique de l’ECMO Veino-Artérielle Bases physiologiques
L’ECMO veino-artérielle (ECMO VA) est de plus en plus utilisée comme thérapeutique de sauvetage au cours des chocs cardiogéniques les plus sévères. Si elle permet de restaurer un débit sanguin, elle entraîne une perturbation majeure de l’hémodynamique des patients. Sur le plan macrocirculatoire, elle baisse la précharge ventriculaire droite, et au contraire élève de la postcharge ventriculaire gauche. Si l’effet net de ces deux actions reste peu prévisible, elles sont responsables de deux complications principales : 1) L’œdème aigu du poumon sous ECMO, très fréquent, qui est associé à une morbidité élevée. 2) La baisse du débit cardiaque natif, pouvant aller jusqu’à son annulation, induisant un risque de thrombose des cavités cardiaques. Un autre l’effet macrocirculatoire de l’ECMO est le ‘syndrome arlequin’, spécifique de la canulation périphérique, qui traduit un conflit de flux dans l’aorte entre le débit de l’ECMO et le débit du cœur natif. Enfin, les formes sévères de choc cardiogénique sont associées à un syndrome inflammatoire systémique marqué, responsable d’une vasoplégie, d’une fuite vasculaire, et de troubles de la microcirculation. Si l’effet de l’ECMO sur ces troubles hémodynamiques médiés par l’inflammation reste mal caractérisé, leur prise en charge représente un axe d’amélioration majeure pour ces patients.
- 12 January 2026
- Published by Societe de Reanimation de Langue Francaise in Médecine Intensive Réanimation
- Vol. 34 (4)
Open AccessImpact hémodynamique de l’ECMO Veino-Artérielle Bases physiologiques
L’ECMO veino-artérielle (ECMO VA) est de plus en plus utilisée comme thérapeutique de sauvetage au cours des chocs cardiogéniques les plus sévères. Si elle permet de restaurer un débit sanguin, elle entraîne une perturbation majeure de l’hémodynamique des patients. Sur le plan macrocirculatoire, elle baisse la précharge ventriculaire droite, et au contraire élève de la postcharge ventriculaire gauche. Si l’effet net de ces deux actions reste peu prévisible, elles sont responsables de deux complications principales : 1) L’œdème aigu du poumon sous ECMO, très fréquent, qui est associé à une morbidité élevée. 2) La baisse du débit cardiaque natif, pouvant aller jusqu’à son annulation, induisant un risque de thrombose des cavités cardiaques. Un autre l’effet macrocirculatoire de l’ECMO est le ‘syndrome arlequin’, spécifique de la canulation périphérique, qui traduit un conflit de flux dans l’aorte entre le débit de l’ECMO et le débit du cœur natif. Enfin, les formes sévères de choc cardiogénique sont associées à un syndrome inflammatoire systémique marqué, responsable d’une vasoplégie, d’une fuite vasculaire, et de troubles de la microcirculation. Si l’effet de l’ECMO sur ces troubles hémodynamiques médiés par l’inflammation reste mal caractérisé, leur prise en charge représente un axe d’amélioration majeure pour ces patients.
- Open Access
- 6 September 2025
- Published by Elsevier in Resuscitation Plus
- Vol. 26, 101090
Reply to ‘Methodological considerations on early cumulative fluid balance and mortality in post-cardiac arrest shock’
- 6 September 2025
- Published by Elsevier in Resuscitation Plus
- Vol. 26, 101090
Open AccessReply to ‘Methodological considerations on early cumulative fluid balance and mortality in post-cardiac arrest shock’
- Open Access
- 17 July 2025
- Published by Elsevier in Resuscitation Plus
- Vol. 25, 101037
Fluid balance after cardiac arrest: Any impact on outcome? Insights from the MIMIC IV database
- 17 July 2025
- Published by Elsevier in Resuscitation Plus
- Vol. 25, 101037
Open AccessFluid balance after cardiac arrest: Any impact on outcome? Insights from the MIMIC IV database
- Open Access
- 5 June 2025
- Published by Elsevier in Annals of Intensive Care
- Vol. 15 (1) , 79-13
Vascular leakage during circulatory failure: physiopathology, impact and treatments
- 5 June 2025
- Published by Elsevier in Annals of Intensive Care
- Vol. 15 (1) , 79-13
Open AccessVascular leakage during circulatory failure: physiopathology, impact and treatments
- 17 January 2025
- Published by Elsevier in Resuscitation
- Vol. 207, 110501
E-CPR: Does ECMO enhance or relieve the pressure on the injured heart?
- 17 January 2025
- Published by Elsevier in Resuscitation
- Vol. 207, 110501
E-CPR: Does ECMO enhance or relieve the pressure on the injured heart?
- Open Access
- 29 August 2023
- Published by Springer Nature in Critical Care
- Vol. 27 (1) , 1-11
FX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial
Background: Vascular leakage is a major feature of acute respiratory distress syndrome (ARDS). We aimed to evaluate the efficacy of FX06, a drug under development that stabilizes interendothelial cell junctions, at reducing vascular leakage during SARS-CoV-2-induced ARDS. Methods: This multicenter, double-blinded, randomized trial included adults with COVID-19-associated ARDS who had received invasive mechanical ventilation for < 5 days and were randomized to receive either intravenous FX06 (400 mg/d, for 5 days) or its vehicle as placebo. The primary endpoint was the lowering—from day 1 to day 7—of the transpulmonary thermodilution-derived extravascular lung-water index (EVLWi). Results: Twenty-five patients were randomized to receive FX06 and 24 the placebo. Although EVLWi was elevated at baseline (median [IQR] 15.6 mL/kg [13.5; 18.5]), its declines from day 1 to day 7 were comparable for FX06 recipients and controls (respectively, − 1.9 [− 3.3; − 0.5] vs. − 0.8 [− 5.5; − 1.1] mL/kg; estimated effect − 0.8 [− 3.1; + 2.4], p = 0.51). Cardiac indexes, pulmonary vascular permeability indexes, and fluid balances were also comparable, as were PaO2/FiO2 ratios and durations of mechanical ventilation. Adverse event rates were similar for the 2 groups, although more FX06 recipients developed ventilator-associated pneumonia (16/25 (64%) vs. 6/24 (24%), p = 0.009). Conclusions: In this unique-dosing–regimen study, FX06 did not lower SARS-CoV-2-induced pulmonary vascular leakage. Future investigations will need to evaluate its efficacy at earlier times during the disease or using other regimens. Trial registration NCT04618042. Registered 5 November 2020.
- 29 August 2023
- Published by Springer Nature in Critical Care
- Vol. 27 (1) , 1-11
Open AccessFX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial
Background: Vascular leakage is a major feature of acute respiratory distress syndrome (ARDS). We aimed to evaluate the efficacy of FX06, a drug under development that stabilizes interendothelial cell junctions, at reducing vascular leakage during SARS-CoV-2-induced ARDS. Methods: This multicenter, double-blinded, randomized trial included adults with COVID-19-associated ARDS who had received invasive mechanical ventilation for < 5 days and were randomized to receive either intravenous FX06 (400 mg/d, for 5 days) or its vehicle as placebo. The primary endpoint was the lowering—from day 1 to day 7—of the transpulmonary thermodilution-derived extravascular lung-water index (EVLWi). Results: Twenty-five patients were randomized to receive FX06 and 24 the placebo. Although EVLWi was elevated at baseline (median [IQR] 15.6 mL/kg [13.5; 18.5]), its declines from day 1 to day 7 were comparable for FX06 recipients and controls (respectively, − 1.9 [− 3.3; − 0.5] vs. − 0.8 [− 5.5; − 1.1] mL/kg; estimated effect − 0.8 [− 3.1; + 2.4], p = 0.51). Cardiac indexes, pulmonary vascular permeability indexes, and fluid balances were also comparable, as were PaO2/FiO2 ratios and durations of mechanical ventilation. Adverse event rates were similar for the 2 groups, although more FX06 recipients developed ventilator-associated pneumonia (16/25 (64%) vs. 6/24 (24%), p = 0.009). Conclusions: In this unique-dosing–regimen study, FX06 did not lower SARS-CoV-2-induced pulmonary vascular leakage. Future investigations will need to evaluate its efficacy at earlier times during the disease or using other regimens. Trial registration NCT04618042. Registered 5 November 2020.
- 20 July 2023
- Published by Elsevier in Seminars in Cell & Developmental Biology
- Vol. 155 (Pt C) , 16-22
Blood endothelium transition and phenotypic plasticity: A key regulator of integrity/permeability in response to ischemia
- 20 July 2023
- Published by Elsevier in Seminars in Cell & Developmental Biology
- Vol. 155 (Pt C) , 16-22
Blood endothelium transition and phenotypic plasticity: A key regulator of integrity/permeability in response to ischemia
- Open Access
- 14 July 2021
- Published by Springer Nature in Critical Care
- Vol. 25 (1) , 1-9
Venoarterial extracorporeal membrane oxygenation as mechanical circulatory support in adult septic shock: a systematic review and meta-analysis with individual participant data meta-regression analysis
Background: While recommended by international societal guidelines in the paediatric population, the use of venoarterial extracorporeal membrane oxygenation (VA ECMO) as mechanical circulatory support for refractory septic shock in adults is controversial. We aimed to characterise the outcomes of adults with septic shock requiring VA ECMO, and identify factors associated with survival. Methods: We searched Pubmed, Embase, Scopus and Cochrane databases from inception until 1st June 2021, and included all relevant publications reporting on > 5 adult patients requiring VA ECMO for septic shock. Study quality and certainty in evidence were assessed using the appropriate Joanna Briggs Institute checklist, and the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach, respectively. The primary outcome was survival to hospital discharge, and secondary outcomes included intensive care unit length of stay, duration of ECMO support, complications while on ECMO, and sources of sepsis. Random-effects meta-analysis (DerSimonian and Laird) were conducted. Data synthesis: We included 14 observational studies with 468 patients in the meta-analysis. Pooled survival was 36.4% (95% confidence interval [CI]: 23.6%–50.1%). Survival among patients with left ventricular ejection fraction (LVEF) < 20% (62.0%, 95%-CI: 51.6%–72.0%) was significantly higher than those with LVEF > 35% (32.1%, 95%-CI: 8.69%–60.7%, p = 0.05). Survival reported in studies from Asia (19.5%, 95%-CI: 13.0%–26.8%) was notably lower than those from Europe (61.0%, 95%-CI: 48.4%–73.0%) and North America (45.5%, 95%-CI: 16.7%–75.8%). GRADE assessment indicated high certainty of evidence for pooled survival. Conclusions: When treated with VA ECMO, the majority of patients with septic shock and severe sepsis-induced myocardial depression survive. However, VA ECMO has poor outcomes in adults with septic shock without severe left ventricular depression. VA ECMO may be a viable treatment option in carefully selected adult patients with refractory septic shock.
- 14 July 2021
- Published by Springer Nature in Critical Care
- Vol. 25 (1) , 1-9
Open AccessVenoarterial extracorporeal membrane oxygenation as mechanical circulatory support in adult septic shock: a systematic review and meta-analysis with individual participant data meta-regression analysis
Background: While recommended by international societal guidelines in the paediatric population, the use of venoarterial extracorporeal membrane oxygenation (VA ECMO) as mechanical circulatory support for refractory septic shock in adults is controversial. We aimed to characterise the outcomes of adults with septic shock requiring VA ECMO, and identify factors associated with survival. Methods: We searched Pubmed, Embase, Scopus and Cochrane databases from inception until 1st June 2021, and included all relevant publications reporting on > 5 adult patients requiring VA ECMO for septic shock. Study quality and certainty in evidence were assessed using the appropriate Joanna Briggs Institute checklist, and the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach, respectively. The primary outcome was survival to hospital discharge, and secondary outcomes included intensive care unit length of stay, duration of ECMO support, complications while on ECMO, and sources of sepsis. Random-effects meta-analysis (DerSimonian and Laird) were conducted. Data synthesis: We included 14 observational studies with 468 patients in the meta-analysis. Pooled survival was 36.4% (95% confidence interval [CI]: 23.6%–50.1%). Survival among patients with left ventricular ejection fraction (LVEF) < 20% (62.0%, 95%-CI: 51.6%–72.0%) was significantly higher than those with LVEF > 35% (32.1%, 95%-CI: 8.69%–60.7%, p = 0.05). Survival reported in studies from Asia (19.5%, 95%-CI: 13.0%–26.8%) was notably lower than those from Europe (61.0%, 95%-CI: 48.4%–73.0%) and North America (45.5%, 95%-CI: 16.7%–75.8%). GRADE assessment indicated high certainty of evidence for pooled survival. Conclusions: When treated with VA ECMO, the majority of patients with septic shock and severe sepsis-induced myocardial depression survive. However, VA ECMO has poor outcomes in adults with septic shock without severe left ventricular depression. VA ECMO may be a viable treatment option in carefully selected adult patients with refractory septic shock.